Restoration of angiogenesis by enalapril in diabetic hindlimb ischemc rats

Biomedical Papers

Volumn 155, Issue 2, 2011, Pages 137-142

  Fallahzadeh, Ali Reza ^a   Khazaei, Majid ^a   Sharifi, Mohammad Reza ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Capillary density; Diabetes; Enalapril; Hind limb ischemia; Rat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NITRIC OXIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL; ARTICLE; BLOOD; DIABETIC ANGIOPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HINDLIMB; ISCHEMIA; MALE; PATHOPHYSIOLOGY; RAT; SKELETAL MUSCLE; VASCULARIZATION; WISTAR RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; ENALAPRIL; HINDLIMB; ISCHEMIA; MALE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; RATS; RATS, WISTAR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; RATTUS;

EID: 79960201561     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2011.026     Document Type: Article

References (29)

1. Ouriel K. Peripheral arterial disease. Lancet 2001;358:1257-64.
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
3. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
4. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-88.
5. Silvestre JS, Levy BI. Molecular basis of angiopathy in diabetes mellitus. Circ Res 2006;98:4-6.
6. Weir MR. Effects of renin-angiotensin system inhibition on endorgan protection: can we do better? Clin Ther 2007;29:1803-24.
7. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S, Imaizumi,T. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002;109:603-11.
8. Li P, Kondo T, Numaguchi Y, Kobayashi K, Aoki M, Inoue N, Okumura K, Murohara T. Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Hypertension 2008;51:252-58.
9. Lloyd PG, Yang HT, Terjung RL. Arteriogenesis and angiogenesis in rat ischemic hindlimb: role of nitric oxide. Am J Physiol Heart Circ Physiol 2001;281:H2528-H2538.
10. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001;104:2344-50.
11. Nematollahi S, Nematbakhsh M, Haghjooyjavanmard S, Khazaei M, Salehi M. Inducible nitric oxide synthase modulates angiogenesis in ischemic hindlimb of rat. Biomed Pap Med.Fac Univ Palacky Olomouc Czech Repub 2009;153:125-29.
12. Baluchnejadmojarad T, Roghani M, Imani A. Protective effect of enalapril on vascular reactivity of the rat aorta. Vascul Pharmacol 2004;40:301-07.
13. Khazaei M, Nematbakhsh M. The effect of hypertension on serum nitric oxide and vascular endothelial growth factor concentrations. A study in DOCA-Salt hypertensive ovariectomized rats. Regul Pept 2006;135:91-94.
14. Nematbakhsh M, Ghadesi M, Hosseinbalam M, Khazaei M, Gharagozloo M, Dashti S, Rajabi P, Rafeian S. Oestrogen promotes coronary angiogenesis even under normoxic conditions. Basic Clin Pharmacol Toxicol 2008;103:273-77.
15. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
16. Simons M. Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol 2005;46:835-37.
17. Kivela R, Silvennoinen M, Lehti M, Jalava S, Vihko V, Kainulainen H. Exercise-induced expression of angiogenic growth factors in skeletal muscle and in capillaries of healthy and diabetic mice. Cardiovasc Diabetol 2008;7:13.
18. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 2005;25:65-70.
19. Gao L, Yu DM. Molecular mechanism of limbs' postischemic revascularization improved by perindopril in diabetic rats. Chin Med J (Engl.) 2008;121:2129-33.
20. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002;105:373-79.
21. Emanueli C, Graiani G, Salis MB, Gadau S, Desortes E, Madeddu P. Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes 2004;53:1096-103.
22. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 2007;101:948-56.
23. Li YJ, Guan H, Hazarika S, Liu CW, Annex BH. Impaired angiogenesis following hind-limb ischemia in diabetes mellitus mice. Chin Med Sci J 2007;22:232-37.
24. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000;102:185-90.
25. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol 2004;164:1531-35.
26. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.
27. Zheng Z, Chen H, Ke G, Fan Y, Zou H, Sun X, Gu Q, Xu X, HO PC. Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondriareactive oxygen species pathway. Diabetes 2009;58:954-64.
28. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 2008;100:1223-32.
29. Donnini S, Solito R, Giachetti A, Granger HJ, Ziche M, Morbidelli L. Fibroblast growth factor-2 mediates Angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium. J Pharmacol Exp Ther 2006;319:515-22.